LSU Health New Orleans

Departments & Centers | Contact | Donate

Administration Basic Sciences Clinical Sciences Centers of Excellence


Adult Clinical Trials

For more information about participating in a clinical trial please contact either Eileen Mederos, RN, Clinical Research Nurse at

*Trials are current as of January 24, 2014.


CA-ALT-801-01-10: A Phase Ib/II Trial of ALT-801 in Combination with Cisplatin and Gemcitabine in Muscle-Invasive or Metastatic Urothelial Cancer


Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma


ECOG 2108: A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer, Version Date 5/31/12

NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

Novartis BDK120 F2303:  A Phase III Randomized, Double-blind, Placebo-controlled Study of BKM120 with Fulvestrant, in Postmenopausal Women with Hormone Receptor-positive HER2-negative AI-treated, Locally-advanced or Metastatic Breast Cancer who Progressed on or after mTOR Inhibitor-based Treatment; Protocol CBKM120F2303

SCUSF 0806: A Phase II placebo-controlled trial of lisinopril and CoregCR® to reduce cardiotoxicity in patients with breast cancer receiving (neo)adjuvant chemotherapy with trastuzumab (Herceptin®)

SWOG 1007:  A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or less


CALGB 80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

ECOG E7208: A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab, in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy

N1048:  A Phase II/III Trial of Neoadjuvant FOLFOX, With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiatin for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision


ASPREE: ASPirin in Reducing Events in the Elderly (ASPREE)


GOG 0258:  A Randomized PH III Trial of Cisplatin and Tumor Volume-Directed Irradiation Followed by Carboplatin and Paclitaxel vs Carboplatin and Paclitaxel vs Carbo and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma

GOG 0274:  Phase III Randomized Study of Cisplatin-Based Chemoradiation with Versus without Adjuvant Chemotherapy comprising Carboplatin and Paclitaxel in Patients with Locally Advanced Cervical Cancer

Head and Neck

BI 1200.131: A Randomized, Double-Blind, Placebo-Controlled, Phase III Study To Evaluate The Efficacy And Safety Of Afatinib (BIBW 2992) As Adjuvant Therapy After Chemo-Radiotherapy In Primary Unresected Patients With Stage III, Iva, Or Ivb Loco-Regionally Advanced Head And Neck Squamous Cell Carcinoma LUX-Head & Neck 2

IRB #7079C: E1305: A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer 

RTOG 0920:  A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally Advanced Resected Head and Neck Cancer

RTOG 1008: A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

RTOG 1016: Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer

HIV+ Malignancy

AMC 083: Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies – Large B cell Lymphoma, Non-Small Cell Lung Malignancy, Anal Cancer, or Cervical Cancer


CALGB 80802: Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies – Large B cell Lymphoma, Non-Small Cell Lung Malignancy, Anal Cancer, or Cervical Cancer

RTOG 1112:  Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma



ECOG 5508: Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

RTOG 0937: Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone To Prophylactic Cranial Irradiation And Consolidative Extra-Cranial Irradiation For Extensive Disease Small Cell Lung Cancer (ED-SCLC)

SWOG S0819:  A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

UbiVac DPV-001:  Randomized Phase II Trial of Cyclophosphamide with Allogeneic Non-small Cell Lung Cancer (NSCLC) Dribble Vaccine alone or with Granulocyte-Macrophage Colony- Stimulating Factor or Imiquimod for Adjuvant Treatment of Definitively-Treated Stage IIIA or IIIB NSCLC


CALGB 70807: The Men’s Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance

IRB #7111C: CALGB 90203: Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy vs Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer

RTOG 0924: Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Ratiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: a Phase III Randomized Trial


SWOG S0931:  A Randomized Study of Everolimus Versus Placebo in Patients with Renal Cell Carcinoma who have Undergone Nephrectomy or Partial Nephrectomy


ECOG E1609:  A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma